Brandon C Rosen

Dr. Brandon C Rosen

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
LRLauren N. Rust
Lauren N. Rust
MRMichael J. Ricciardi
Michael J. Ricciardi
SLSavannah S. Lutz
Savannah S. Lutz
SYSofiya Yusova
Sofiya Yusova
JLJohan J. Louw
Johan J. Louw
Benjamin BurwitzBenjamin Burwitz
Benjamin Burwitz
Yellow fever virus (YFV) infection is fatal in 5%–10% of the 200,000 yearly cases. There is currently no available antiviral treatment. We showed previously that administration of 50 mg/kg of a YFV-specific neutralizing monoclonal antibody (nmAb) at 2 days postinfection (dpi), prior to the onset of severe disease, protected YFV-infected rhesus macaques from death. To further explore the clinical applicability of our nmAb MBL-YFV-01, we treated rhesus macaques with a lower dose (10 mg/kg) of this nmAb prophylactically or therapeutically at 3.5 dpi. We show that a single prophylactic or therapeutic i.v. dose of our nmAb protects rhesus macaques from death following challenge. A comprehensive analysis of 167 inflammatory cytokine and chemokines revealed that protection was associated with significantly reduced expression of 125 of these markers, including type I IFN, IL-6, and CCL2. This study further expands the potential clinical use of our YFV-specific nmAb, which could be used during an outbreak for immediate prophylactic immunity or for patients with measurable serum viremia.